Decoding Rongchang Biotech's Turnaround: The "High Certainty" of a "Purebred" Innovative Drug Company

Ask AI · How does Rongchang Biopharmaceutical achieve profit certainty through local commercialization?

China’s innovative pharmaceutical industry is bidding farewell to extensive growth and fully entering a new stage of high-quality, in-depth development. Only “pure-blood” innovative pharmaceutical companies that focus on original innovation, establish independent commercialization barriers, and complete global strategic layouts can navigate industry cycles, secure growth certainty, and stand firm in the long-term market.

Rongchang Biopharmaceutical is a benchmark enterprise under this trend. By 2025, it will solidify its foundation through local commercialization of core products, open up growth space through global BD collaboration, and build core competitiveness through an efficient self-research system, paving a path for stable profitability, certain growth, and promising development.

1. Financial structure continuously optimized; commercialization capability accumulates and bursts forth

2025 is a major year for BD in China’s innovative pharmaceuticals. BD revenue brings valuable cash flow to companies, but BD relies on “timing, location, and harmony,” which has a certain degree of randomness; long-term profitability depends on commercialization capability. The impressive performance of Rongchang Biopharmaceutical’s 2025 financial report precisely confirms this underlying logic—escaping the reliance on short-term cash injections from one-time large BD payments and relying on self-researched products to delve into the local market and achieve deep commercialization is the only pathway for “pure-blood” innovative pharmaceutical companies to traverse industry cycles and establish high growth certainty.

As a benchmark for local original innovation, Rongchang Biopharmaceutical achieved revenue of 3.251 billion yuan in 2025, a year-on-year increase of 89.36%, with a total profit of 710 million yuan, marking a milestone turnaround to profitability.

This report card marks Rongchang Biopharmaceutical’s complete farewell to the short-term model of relying on a $200 million overseas BD upfront payment for Weidisitun antibody to boost profits in 2021, with its growth logic having undergone a qualitative change. At that time, Taizetiximab and Weidisitun antibody had just been launched and were still in the market introduction phase, with limited hospital market coverage and weak self-commercialization capabilities.

By 2025, Rongchang Biopharmaceutical’s profit structure was completely restructured, with the performance foundation mainly supported by the domestic terminal volume of core products Taizetiximab and Weidisitun antibody. The annual revenue of the core biopharmaceutical sector reached 2.307 billion yuan, accounting for 70.97% of total revenue, with a steady year-on-year growth of 35.80%, becoming the core pillar of profit.

Image source: Rongchang Biopharmaceutical 2025 Annual Report

From a long-term growth trajectory perspective, Rongchang Biopharmaceutical’s domestic commercialization sales revenue has maintained a steady upward trend from 2021 to 2025, growing from 131 million yuan in 2021 to 2.271 billion yuan in 2025, an increase of 1633.59%. This leap in growth further confirms the solid results of core product commercialization.

At the same time, the operational quality of Rongchang Biopharmaceutical has also undergone leapfrog optimization. On one hand, production processes continue to mature, coupled with scaled production capacity and improved supply chain systems, achieving significant cost control. In 2025, Rongchang Biopharmaceutical’s overall gross profit margin was 87.3%, an increase of 6.9 percentage points year-on-year; the gross profit margin for commercialized products was 84.3%, a year-on-year increase of 3.7 percentage points; the gross profit margin for biopharmaceuticals was 83.41%, a year-on-year increase of 2.79 percentage points, solidifying a high gross margin barrier. On the other hand, the specialized sales team is maturing, hospital coverage is continuously expanding, academic promotion is becoming more refined, and the sales expense ratio is steadily declining, with 2025 being 48.9% (the rate of domestic commercialized product sales revenue), down 6.9 percentage points year-on-year.

Relying on the triple optimization of revenue structure, cost control, and sales efficiency, Rongchang Biopharmaceutical’s overall commercialization maturity now ranks first among similar innovative pharmaceutical companies in China.

Moreover, deepening and expanding channels further solidifies Rongchang Biopharmaceutical’s growth foundation. In the field of immunity, the core product Taizetiximab completed access to only 495 hospitals in 2021, while in 2025, this number has exceeded 1200, coupled with the renewal of medical insurance for systemic lupus erythematosus (SLE) indications and the inclusion of new myasthenia gravis (MG) indications in medical insurance, the accessibility for patients with already listed indications is expected to significantly improve. Additionally, the approval of two potential indications, Sjögren’s syndrome (SjD) and IgA nephropathy (IgAN), is expected to continuously open up growth space in the immunity sector.

In the oncology sector, Weidisitun antibody (the first domestically produced original ADC), has increased hospital access from 274 in 2021 to 1050 in 2025, providing solid support for terminal volume for already listed indications. Coupled with the continuous expansion of indications, in 2025 it gained approval for HER2-positive advanced breast cancer with liver metastasis, and in March 2026, a new approval for HER2 low-expressing breast cancer with liver metastasis; another application for a combination therapy for first-line treatment of HER2-expressing urothelial carcinoma has already been submitted in 2025, which will reshape the standard treatment landscape for advanced urothelial carcinoma in China once approved.

Now, Rongchang Biopharmaceutical has completed a qualitative transformation from BD blood transfusion to self-sustaining core business. With core products laying the groundwork, the relay of medical insurance and new indications, and continuous optimization of operational efficiency, there is ample room for future product volume and per capita efficiency to improve. The solid and mature local commercialization strength is the hard-core backing for Rongchang Biopharmaceutical’s profitability stability and growth certainty.

2. Frequent heavyweight BDs accelerate the internationalization process; certainty of results continues to be fulfilled

If Rongchang Biopharmaceutical’s BD in 2021 was “an accidental event,” then now with four drug BDs achieved, it to some extent indicates that this is a “necessity” based on the transition from “providing a single asset” to “providing strategic value,” and its BD quality and global value realization capability rank among the top in domestic innovative pharmaceutical companies.

So far, Rongchang Biopharmaceutical has achieved global licensing for four core drugs: Weidisitun antibody, Taizetiximab, RC28, and RC148, with a total transaction amount exceeding $12.6 billion, including over $1 billion in upfront payments (including RC28 converted at the current RMB exchange rate), which not only provides short-term cash flow but also locks in long-term global revenue in advance.

Among them, the most representative is the “new ace” RC148, a novel dual-specificity antibody targeting PD-1/VEGF that made a stunning debut at the 2026 JPM conference. The first clinical data disclosed showed that when combined with platinum-based chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC), its objective response rate (ORR) has the potential to be best in class, and safety is well demonstrated.

With a series of impressive clinical data, in January 2026, Rongchang Biopharmaceutical granted exclusive rights for the development, production, and commercialization of RC148 outside of Greater China to global pharmaceutical giant AbbVie, with a total transaction amount of $5.6 billion, including $650 million in upfront payments, up to $4.95 billion in milestone payments, and double-digit tiered royalties on net sales outside of Greater China. AbbVie’s involvement not only confirms RC148’s global competitive edge but also lays a solid foundation for Rongchang Biopharmaceutical’s subsequent pipeline BD.

In addition to the heavyweight collaboration on RC148, Weidisitun antibody, Taizetiximab, and RC28 have also completed multi-regional global licensing, covering the entire oncology, immunity, and ophthalmology sectors. The specific core transaction details are as follows:

The continued breakthroughs in BD are strongly supported by the robust strength of pipeline innovation. Many products in Rongchang Biopharmaceutical’s pipeline also have first-in-class and best-in-class potential, with significant clinical and commercial value. Potential molecules such as RC278 and RC118 continue to shine at global top academic conferences. Preliminary clinical data for RC278 (targeting CDCP1 ADC) presented at the 2026 JPM conference showed that a single dose could achieve deep and lasting tumor regression in colorectal cancer PDX models, even leading to complete remission, with good safety; RC118 (targeting CLDN18.2 ADC) demonstrated considerable objective response rates for Claudin18.2 positive gastric cancer patients after multiple lines of treatment at the 2025 ESMO conference.

These clinical breakthroughs have allowed Rongchang Biopharmaceutical’s BD layout to evolve from “one-time success” to “continuous realization,” proving that its BD capability is not accidental but a necessary result based on original innovation strength and globally leading clinical data. As more potential pipelines advance, Rongchang Biopharmaceutical’s global value will continue to be released, further consolidating its voice in the global innovative pharmaceutical field.

3. Dual improvements in R&D efficiency and outcomes; solidifying the core “lifeline”

The R&D pipeline is the “lifeline” of innovative pharmaceutical companies.

While BD continues to fulfill its promise and commercialization steadily profits, Rongchang Biopharmaceutical’s R&D investment has also shown a trend of quality improvement and efficiency enhancement. In 2025, Rongchang Biopharmaceutical’s R&D expenses were 1.219 billion yuan, a year-on-year decrease of 20.85%, but this change does not indicate a reduction in R&D investment or weakening of innovation capability; rather, it reflects a rational adjustment of R&D structure, with overseas costs borne by partners and a precise focus on the pipeline.

On one hand, after completing overseas BD licensing for products like Taizetiximab and RC148, the corresponding overseas clinical development costs are borne by partners, allowing Rongchang Biopharmaceutical to concentrate solely on domestic self-research; on the other hand, Rongchang Biopharmaceutical has streamlined inefficient early projects, concentrating resources on deepening antibody and fusion protein platforms, antibody-drug conjugate (ADC) platforms, dual-specificity antibody platforms, dual-specificity antibody ADC platforms, and PR-ADC payload recovery platforms, while increasing the proportion of pivotal Phase III trials in 2025, significantly optimizing the efficiency of R&D expenditure.

In terms of R&D investment, Rongchang Biopharmaceutical’s domestic R&D expenses are roughly on par with previous years, without significant fluctuations, but the precision and output value of R&D investment have significantly improved, especially in September to October 2025, when Rongchang Biopharmaceutical’s research achievements made a stunning appearance at major academic conferences and core academic journals in Europe and the United States, showcasing strong innovation strength.

The Phase III study results of Weidisitun antibody for first-line urothelial carcinoma were presented in a verbal report at the 2025 ESMO conference’s chair forum and simultaneously published in the New England Journal of Medicine, with a median PFS of 13.1 months, median OS of 31.5 months, ORR of 76.1%, and DCR of 91.4%. At the 2025 ASN annual meeting, the Phase III study of Taizetiximab for IgA nephropathy was rated as a “breakthrough report,” achieving a significant reduction of 55% in the urine protein to creatinine ratio (UPCR), providing a new solution for global autoimmune disease treatment. RC148 presented Phase I/II study data for single-agent first-line and combined second-line treatment of non-small cell lung cancer at the 2025 ESMO-IO conference, with a single-agent ORR of 61.9%, DCR of 100%, and RC148 (20mg/kg) combined with docetaxel showing an ORR of 66.7% and DCR of 95.2%.

As a “pure-blood” innovative pharmaceutical company, Rongchang Biopharmaceutical has always regarded R&D as its core competitiveness. In 2025, R&D investment accounted for 37.49% of revenue, far exceeding the industry average; there are 864 R&D personnel, with over 44% holding PhDs or Master’s degrees, and the core team is stable.

Rongchang Biopharmaceutical has validated the growth certainty of “pure-blood” innovative pharmaceutical companies with solid achievements and outcomes derived from original innovation. By 2025, domestic commercialization revenue has become the main source of Rongchang Biopharmaceutical’s revenue. Even excluding BD-related income, relying solely on the local volume of core products like Taizetiximab and Weidisitun antibody, Rongchang Biopharmaceutical will have the capability to achieve revenue balance and maintain stable profitability in 2026; the foundation for endogenous growth has been fully solidified, demonstrating substantial growth resilience.

As domestic product indications steadily expand, commercialization capabilities continue to be released, BD value continues to be fulfilled, and R&D results are consistently realized, Rongchang Biopharmaceutical’s growth certainty will be further strengthened, setting a replicable benchmark for the domestic innovative pharmaceutical industry.

Author’s statement: Personal views, for reference only.